Todd Fehniger, MD, PhD

Bone Marrow Transplant Specialist

Todd Fehniger

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Clinical Expertise

  • Lymphoma

  • Cellular Therapy

  • Bone Marrow Transplantation

Primary Academic Title

Professor of Medicine, Division of Oncology, Sections of Stem Cell Biology and Bone Marrow Transplantation, WashU Medicine

Board Certification

  • 2006: American Board of Internal Medicine, Internal Medicine
  • 2009: American Board of Internal Medicine, Medical Oncology

Training

  • 2002 - 2004: Intern and Resident, Internal Medicine, WashU Medicine, St. Louis, MO
  • 2004 - 2008: Fellow, Hematology and Oncology, WashU Medicine, St. Louis, MO

Education

  • 2000: PhD, Immunology, Ohio State University, Columbus, OH
  • 2002: MD, Ohio State University, Columbus, OH

Research & Selected Publications

Research Interest

The long-term goals of my laboratory are to better understand the molecular programs that regulate natural killer (NK) cell development and activation and translate basic NK cell biology into novel treatments for patients with cancer. My clinical interests are lymphoma, cellular therapy and hematopoietic stem-cell transplantation.

Research Publications

A new immunotherapy ROR: Proximal ROR1 domain targeting breast cancer via monoclonal antibodies and CAR NK cells
Authors:

Fehniger TA

Journal & Year:

Mol Ther | 2026

Large B cell lymphoma microenvironment archetype profiles
Authors:

Li X, Singhal K, Deng Q, one or more additional authors omitted Fehniger TA, one or more additional authors omitted Green MR

Journal & Year:

Cancer Cell | 2025

First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Authors:

El-Khoueiry A, Saavedra O, Thomas J, one or more additional authors omitted Fehniger TA, one or more additional authors omitted Lopez J

Journal & Year:

Clin Cancer Res | 2025

Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer
Authors:

Lee S, Ricci B, Tran J, one or more additional authors omitted Fehniger TA, Faccio R

Journal & Year:

Nat Commun | 2025

Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma
Authors:

Zhou AY, Marin ND, Afrin S, one or more additional authors omitted Fehniger TA

Journal & Year:

J Immunol | 2025

MicroRNA-146a deficiency enhances host protection against murine cytomegalovirus
Authors:

Wong P, Leong JW, Sohn H, one or more additional authors omitted Fehniger TA

Journal & Year:

Eur J Immunol | 2024

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
Authors:

Ramirez CA, Becker-Hapak M, Singhal K, one or more additional authors omitted Fehniger TA

Journal & Year:

Blood Adv | 2024

Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation
Authors:

Foltz JA, Tran J, Wong P, one or more additional authors omitted Fehniger TA

Journal & Year:

Sci Immunol | 2024